Annovis Bio

Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The firm compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It also develops ANVS405 for protecting the brain after traumatic brain injury and/or stroke, and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.

Anavex Life Sciences

Biogen

Cassava Sciences Inc

Biogen's Aduhelm performed no better than placebo in non-ApoE4 carriers and only slightly slowed down the progression of Alzheimer's disease in ApoE4 carriers.

Detours In The Golden Age Of Alzheimer's Drug Stock Investments

NEW YORK--(BUSINESS WIRE)---- $ANVS--The law firm of Kirby McInerney LLP is investigating potential claims against Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS). The investigation concerns whether Annovis has violated the federal securities laws and/or engaged in other unlawful business practices. Annovis is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases. The Company's lead candidate is Posiphen, or ANVS401, an orally administered drug that purpo

INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Annovis Bio, Inc.

New York, New York--(Newsfile Corp. - August 2, 2021) - Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Annovis Bio, Inc. common stock (NYSE American: ANVS).Annovis is a clinical-drug company and its lead drug candidate is ANVS401 (a/k/a Posiphen), which is used to treat Parkinson's and Alzheimer's diseases. Annovis is conducting two Phase 2 clinical trials with Posiphen. One trial is only for Alzheimer's patients and the...

Wolf Popper LLP Announces Investigation on Behalf of Purchasers of Annovis Bio, Inc. (ANVS) Common Stock

GT Biopharma Inc

Inovio Pharmaceuticals

Are penny stocks worth it? Take a look at these 3 seeing explosive moves this year.

Former Biotech Penny Stocks Seeing Explosive Moves In 2021

ANVS401's Interim Clinical Data Demonstrate Statistically Significant Improvements in Cognitive Function in AD Patients and Motor Function in PD PatientsBiomarkers Demonstrate Reduction in Neurotoxic Proteins, Improvement in Axonal Health and Reduction in Inflammation Levels Next Clinical Data Readout Expected in the Third Quarter Berwyn, Pennsylvania--(Newsfile Corp. - July 30, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today said...

Annovis Bio Pleased by Positive Interim Results from Ongoing Phase II Clinical Trials of ANVS401 (Posiphen) for the Treatment of Alzheimer's Disease and Parkinson's Disease

NEW YORK, July 30, 2021 /PRNewswire/ -- Prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") is investigating potential violations of the federal securities laws by Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE American: ANVS). BLB&G is investigating whether Annovis misled investors regarding the efficacy of its Alzheimer's drug, Posiphen.

Investigation Alert: Bernstein Litowitz Berger & Grossmann LLP Announces Investigation of Annovis Bio, Inc. and Encourages Investors to Contact the Firm

A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.

Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday

Shares of ANVS stock are plummeting on Thursday after Annovis Bio reported weak results from two clinical trials for its leading drug. The post ANVS Stock: The Alzheimer's Drug News That Has Annovis Bio Plunging Today appeared first on InvestorPlace.

ANVS Stock: The Alzheimer's Drug News That Has Annovis Bio Plunging Today

The stock price of Annovis Bio Inc (NYSEAMERICAN: ANVS) fell by over 57% during intraday trading. This is why it happened.

ANVS Stock Fell Over 57% Intraday: Why It Happened

Berwyn, Pennsylvania--(Newsfile Corp. - July 28, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, with data from two phase 2 studies showing its lead compound improves cognition in AD patients and motor function in PD patients, is presenting new clinical efficacy and biomarker data of its drug ANVS401 during a one hour panel presentation, beginning...

Annovis Bio Presents New Clinical and Biomarker Data at 2021 Alzheimer's Association International Conference

New efficacy and biomarker data to be featured in panel presentation on Wednesday, July 28. A poster presentation featuring positive clinical outcome data from the Company's two Phase 2a studies will be available on Monday, July 26Berwyn, Pennsylvania--(Newsfile Corp. - July 23, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, with data from two phase 2 studies showing its lead compound improves cognition in AD patients and motor function in PD patients, today announced that it will present new data for its lead product candidate, ANVS401, at the 2021 Alzheimer's Association...

Annovis Bio to Present New Data at 2021 Alzheimer's Association International Conference

Safety and tolerability data for Cohort 2 of the Discover Study reviewed by Data Safety Monitoring Board, allowing the study to proceed with the final cohortBerwyn, Pennsylvania--(Newsfile Corp. - July 20, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, with data from two phase 2 studies showing its lead compound improves cognition in AD patients and motor function in PD patients, today announced that the Data Safety Monitoring Board (DSMB) has reviewed the safety and tolerability data for Cohort 2...

Annovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer's Study

Eli Lilly

Prothena

Treating Alzheimer's is extremely difficult, but these innovative companies are taking a stab at it.

Got $2,500? Check Out These 3 Alzheimer's Therapy Stocks

Moderna

Good news! There's a way to avoid this portfolio pain -- and it doesn't involve avoiding the whole sector.

Here's Why The Biotech Stocks You Bought Keep Going Down

Both are making Alzheimer's drugs, but only one can claim success as of today.

Better Biotech Stock: Biogen vs. Annovis Bio

Brooklyn ImmunoTherapeutics

Citius Pharmaceuticals

Jazz Pharmaceuticals

Mind Medicine MindMed

SpringWorks Therapeutics Inc

Pharma stocks like MNMD stock and ANVS stock offer investors long-term growth potential in a market on track to hit a value of $1.70 trillion. The post 7 Top-Rated Pharmaceutical Companies to Invest In for July appeared first on InvestorPlace.

7 Top-Rated Pharmaceutical Companies to Invest In for July

Berwyn, Pennsylvania--(Newsfile Corp. - July 2, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, with data from two phase 2 studies showing its lead compound improves cognition in AD patients and motor function in PD patients, today announced that its abstract has been accepted at the Alzheimer's Association International Conference (AAIC), which will be held...

Annovis Bio to Present Data at Alzheimer's Association International Conference 2021 Highlighting Positive Clinical Outcomes from Its Two Phase 2a Trials

Berwyn, Pennsylvania--(Newsfile Corp. - July 1, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company that addresses Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, with data from two phase 2 studies showing its lead compound improves cognition in AD patients and motor function in PD patients, today announced its CEO, Maria L. Maccecchini, Ph.D., was named the winner of the 2021 PACT Enterprise Award...

Annovis Bio CEO Wins 2021 PACT Enterprise Award for Life Sciences and Healthcare CEO

Berwyn, Pennsylvania--(Newsfile Corp. - June 24, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria L. Maccecchini, Ph.D., was selected as a Life Sciences and Healthcare CEO finalist in the 2021 PACT Enterprise Awards. Hosted by the Philadelphia Alliance for Capital and Technologies (PACT), whose vision is to be the go-to...

Annovis Bio CEO Selected as a Finalist in the 2021 PACT Enterprise Awards

New approaches to treating Alzheimer's could mean even bigger gains in the future.

These 2 Biotech Stocks Are Up 1,000% This Year

Data doesn't lie. These companies have the potential to quickly steal the spotlight.

Ignore Biogen: 3 Reasons These Stocks Will Be Better Alzheimer's Investments

Arvinas Inc

Virtus LifeSci Biotech Clinical Trials ETF

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

Biohaven Pharmaceutical Hld

Loncar Cancer Immunotherapy ETF

Denali Therapeutics

First Trust NYSE Arca Biotechnology Index Fund

Amplify Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

abrdn Life Sciences Investors 

iShares Nasdaq Biotechnology ETF

Defiance Nasdaq Junior Biotechnology ETF

INmune Bio Inc

Intra-Cellular Therapies

Karuna Therapeutics Inc

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Invesco Dynamic Biotechnology & Genome ETF

Supernus Pharmaceuticals

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector.

Biotechs Ready To Roar

Berwyn, Pennsylvania--(Newsfile Corp. - June 10, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its participation in 2021 BIO Digital, the premier biotech event, taking place online June 10-11 & 14-18, 2021.A corporate presentation by Maria L. Maccecchini, Ph.D., CEO of Annovis Bio, will be available to registered attendees beginning at 9:00 a.m....

Annovis Bio to Present at 2021 BIO Digital

With updates from clinical trials expected as soon as this month, anything is possible.

This Biotech Stock Is Up 884% In 2021, But It Could Go Even Higher

FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in their portfolio.

3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug

News for Annovis Bio Stock (ANVS)